Savara Inc (NASDAQ:SVRA) Stock Position Raised by Sphera Funds Management LTD.

Sphera Funds Management LTD. raised its holdings in shares of Savara Inc (NASDAQ:SVRA - Free Report) by 115.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,211,533 shares of the company's stock after acquiring an additional 648,426 shares during the period. Sphera Funds Management LTD. owned approximately 0.71% of Savara worth $3,719,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in SVRA. Rosalind Advisors Inc. acquired a new stake in Savara in the 4th quarter valued at about $8,151,000. Nantahala Capital Management LLC raised its holdings in shares of Savara by 45.2% in the 4th quarter. Nantahala Capital Management LLC now owns 7,525,259 shares of the company's stock worth $23,103,000 after purchasing an additional 2,344,308 shares in the last quarter. Emerald Advisers LLC acquired a new stake in Savara during the fourth quarter valued at approximately $7,161,000. Farallon Capital Management LLC boosted its holdings in Savara by 49.9% during the fourth quarter. Farallon Capital Management LLC now owns 6,835,000 shares of the company's stock worth $20,983,000 after buying an additional 2,275,000 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C grew its position in Savara by 23.2% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 7,964,000 shares of the company's stock worth $24,449,000 after buying an additional 1,498,223 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.

Savara Stock Down 8.9%

NASDAQ SVRA traded down $0.28 during trading on Wednesday, reaching $2.86. 701,878 shares of the company's stock were exchanged, compared to its average volume of 953,671. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara Inc has a fifty-two week low of $2.26 and a fifty-two week high of $5.11. The company's fifty day simple moving average is $2.96 and its 200-day simple moving average is $3.01. The firm has a market capitalization of $494.31 million, a PE ratio of -6.65 and a beta of 0.44.

Savara (NASDAQ:SVRA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.12). Sell-side analysts predict that Savara Inc will post -0.45 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and issued a $6.00 target price on shares of Savara in a report on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Savara presently has a consensus rating of "Moderate Buy" and an average price target of $8.83.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.